Daurismo Background
Daurismo Background

DAURISMO is the first and only hedgehog pathway inhibitor in the treatment of AML

document icon

Read the full press release about
the FDA approval of DAURISMO

Find Financial Assistance

Help identifying financial
assistance resources 

Learn more

hands icon

Resources that may help your
patients with some of their
day-to-day challenges

Learn more

Full Prescribing Information,
including BOXED WARNING
and Medication Guide

AML=acute myeloid leukemia; LDAC=low-dose cytarabine.